My point is if those costs are included in the FY accounts being used to calculate break-even, then the revenue also needs to be included. If you are excluding BARDA revenue and costs from your analysis then that's fine, but the company doesn't in its full year statements.
Polynovo’s Novosorb is a med-tech Swiss Army Knife, page-23
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.58 |
Change
0.025(0.98%) |
Mkt cap ! $1.763B | |||
| Open | High | Low | Value | Volume |
| $2.53 | $2.58 | $2.46 | $1.717M | 679.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 50 | 29845 | $2.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.58 | 3256 | 7 |
View Market Depth
| Last trade - 13.05pm 21/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |